NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome has recently become an intriguing target of several chronic and viral diseases. Here, we argue that targeting NLRP3 inflammasome could be a strategy to prevent cardiovascular outcomes [fulminant myocarditis, heart failure, venous thromboembolism (VTE)] and acute respiratory distress syndrome (ARDS) in patients with SARS-CoV-2 infection. We discuss the rationale for NLRP3 targeting in clinical trials as an effective therapeutic strategy aimed to improve prognosis of COVID-19, analyzing the potential of two therapeutic options (tranilast and OLT1177) currently available in clinical practice.
About The Author
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab
Quantum chemical insight into molecular structure, NBO analysis of the hydrogen-bonded interactions, spectroscopic (FT-IR, FT-Raman), drug likeness and molecular docking of the novel anti COVID-19 molecule 2-[(4,6-diaminopyrimidin-2-yl)sulfanyl]-N-(4-fluorophenyl)acetamide – dimer
CDC CDC Newsroom Coronavirus COVID19 Disease flu Health health threats healthy choice Infection influenza Letter Media MEDLINE National Center for Biotechnology Information National Institutes of Health National Library of Medicine NCBI Newsroom NIH NLM Online Outbreak Pandemic Patients Potential Press prevention protecting people PubMed Abstract Release Report Review SARSCoV2 saving lives saving money science secure nation Study Telebriefing Treatment Update US federal agency Vaccine virus